Research programme: kinase inhibitors - Nerviano Medical Sciences

Drug Profile

Research programme: kinase inhibitors - Nerviano Medical Sciences

Alternative Names: NMS-088; NMS-P088; NMS-P715; NMS-P948; PHA-680626; PHA-680632

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Nerviano Medical Sciences
  • Class Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors; Bcr-abl tyrosine kinase inhibitors; CDC7 protein kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Phosphotransferase inhibitors; Proto oncogene protein c-kit inhibitors; TTK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Dec 2016 Nerviano Medical Sciences plans clincal trials for NMS P088 in 2017 (Nerviano Medical Sciences pipeline, December 2016)
  • 29 Nov 2016 Pharmacodynamics data from a preclinical studies in Cancer presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics(EORTC-NCI-AACR-2016)
  • 09 May 2016 Preclinical development is ongoing in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top